Innovent Biologics and AnHeart Therapeutics receive NMPA breakthrough designation for taletrectinib

The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors

Thermo Fisher Scientific extends partnership with Symphogen to support biopharma

Thermo Fisher and Symphogen extend their collaboration using innovative and efficient workflows to improve data confidence, aiding the creation of new cancer treatments

Alps Pharma launches a new water soluble Isoquercetin

Eubio Isoquercetin derived from Sophora Japonica is expected to deliver more Quercetin to the body via small doses of Isoquercetin.

HitGen completes research collaboration with MTPC

Collaboration with MTPC to discover novel hit compounds for multiple drug targets

Sumitomo Dainippon Pharma Oncology appoints Jatin J. Shah as Chief Medical Officer

Dr. Shah will lead strategic and operational clinical development of the company's diverse pipeline

Vicore advances on new chemical entity from VP03 program

Four additional AT2R agonists are expected to finalize preclinical evaluation during 2022

Daewoong Pharmaceutical posts strong financials in 2021

Daewoong delivered KRW 1.055 trillion in sales, KRW 95.5 billion in operating profit and KRW 40.5 billion in net profit.

Prestige BioPharma’s Tuznue receives EU-GMP certification

Resolution Therapeutics strengthens its team with two new appointments

Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance

Poxel’s PXL065 granted FDA fast track designation for X-linked adrenoleukodystrophy

Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear